Epigenetic silencing mediated by CpG island methylation: Potential as a therapeutic target and as a biomarker

Drug Resistance Updates

Volumn 7, Issue 4-5, 2004, Pages 267-278

  Teodoridis, Jens M ^a   Strathdee, Gordon ^a   Brown, Robert ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

CpG islands; DNMT; Epigenetics; Histones; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5,6 DIHYDROAZACITIDINE; ALKYLATING AGENT; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; DOXORUBICIN; EPIRUBICIN; FAZARABINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HYDROXAMIC ACID DERIVATIVE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RETINOIC ACID; TAXOID; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL TRIAL; CPG ISLAND; DNA DAMAGE; DNA METHYLATION; DNA MODIFICATION; DNA REPAIR; DNA SEQUENCE; DOSE RESPONSE; DRUG ACTIVATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG SENSITIZATION; DRUG TARGETING; EPIGENETICS; GENE FUNCTION; GENE INACTIVATION; GENE SILENCING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; IC 50; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SOLID TUMOR; SOMATIC CELL; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 7944230161     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2004.06.005     Document Type: Article

References (152)

1. A. Abdollahi, D. Pisarcik, D. Roberts, J. Weinstein, P. Cairns, and T.C. Hamilton LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer J. Biol. Chem. 278 2003 6041 6049
2. Y. Akiyama, N. Watkins, H. Suzuki, K.W. Jair, M. van Engel, M. Esteller, H. Sakai, C.Y. Ren, Y. Yuasa, J.G. Herman, and S.B. Baylin GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer Mol. Cell. Biol. 23 2003 8429 8439
3. T. Ando, M. Nishimura, and Y. Oka Decitabine (5-aza-2′- deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells Leukemia 14 2000 1915 1920
4. S. Anttila, J. Hakkola, P. Tuominen, E. Elovaara, K. Husgafvel- Pursiainen, A. Karjalainen, A. Hirvonen, and T. Nurminen Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking Cancer Res. 63 2003 8623 8628
5. C.N. Arnold, A. Goel, and C.R. Boland Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines Int. J. Cancer 106 2003 66 73
6. K.E. Bachman, J.G. Herman, P.G. Corn, A. Merlo, J.F. Costello, W.K. Cavenee, S.B. Baylin, and J.R. Graff Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers Cancer Res. 59 1999 798 802
7. A.J. Bannister, P. Zegerman, J.F. Partridge, E.A. Miska, J.O. Thomas, R.C. Allshire, and T. Kouzarides Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain Nature 410 2001 120 124
8. M.S. Bartolomei, and S.M. Tilghman Genomic imprinting in mammals Ann. Rev. Genet. 31 1997 493 525
9. T. Bianco, G. Chenevix-Trench, D.C. Walsh, J.E. Cooper, and A. Dobrovic Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer Carcinogenesis 21 2000 147 151
10. D. Biniszkiewicz, J. Gribnau, B. Ramsahoye, F. Gaudet, K. Eggan, D. Humpherys, M.A. Mastrangelo, Z. Jun, J. Walter, and R. Jaenisch Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality Mol. Cell. Biol. 22 2002 2124 2135
11. A.P. Bird, and A.P. Wolffe Methylation-induced repression - belts, braces, and chromatin Cell 99 1999 451 454
12. R. Brown, and G. Strathdee Epigenomics and epigenetic therapy of cancer Tr. Mol. Med. 8 2002 S43 S48
13. D.S. Byun, K. Cho, B.K. Ryu, M.G. Lee, M.J. Kang, H.R. Kim, and S.G. Chi Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas Cancer Res. 63 2003 7068 7075
14. E.E. Cameron, K.E. Bachman, S. Myohanen, J.G. Herman, and S.B. Baylin Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat. Genet. 21 1999 103 107
15. K. Camphausen, W. Burgan, M. Cerra, K.A. Oswald, J.B. Trepel, M.J. Lee, and P.J. Tofilon Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275 Cancer Res. 64 2004 316 321
16. L. Catley, E. Weisberg, Y.T. Tai, P. Atadja, S. Remiszewski, T. Hideshima, N. Mitsiades, R. Shringarpure, R. LeBlanc, and D. Chauhan NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma Blood 102 2003 2615 2622
17. T.F. Chan, T.H. Su, K.T. Yeh, J.Y. Chang, T.H. Lin, J.C. Chen, S.S. Yuang, and J.G. Chang Mutational, epigenetic and expressional analyses of caveolin-1 gene in cervical cancers Int. J. Oncol. 23 2003 599 604
18. T. Chen, Y. Ueda, J.E. Dodge, Z. Wang, and E. Li Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b Mol. Cell. Biol. 23 2003 5594 5605
19. P.G. Corn, S.J. Kuerbitz, M.M. van Noesel, M. Esteller, N. Compitello, S.B. Baylin, and J.G. Herman Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation Cancer Res. 59 1999 3352 3356
20. F.F. Costa, N.V. Verbisck, A.C. Salim, D.F. Ierardi, L.C. Pires, R.M. Sasahara, M.C. Sogayar, S.M. Zanata, A. Mackay, and M. O'Hare Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors Oncogene 23 2004 1481 1488
21. J.F. Costello, M.C. Fruhwald, D.J. Smiraglia, L.J. Rush, G.P. Robertson, X. Gao, F.A. Wright, J.D. Feramisco, P. Peltomaki, and J.C. Lang Aberrant CpG-island methylation has non-random and tumour-type-specific patterns Nat. Genet. 24 2000 132 138
22. S. Cote, D. Sinnett, and R.L. Momparler Demethylation by 5-aza-2′-deoxycytidine of specific 5-methylcytosine sites in the promoter region of the retinoic acid receptor beta gene in human colon carcinoma cells Anticancer Drugs 9 1998 743 750
23. A. Dallol, D. Krex, L. Hesson, C. Eng, E.R. Maher, and F. Latif Frequent epigenetic inactivation of the SLIT2 gene in gliomas Oncogene 22 2003 4611 4616
24. R. Dammann, C. Li, J.H. Yoon, P.L. Chin, S. Bates, and G.P. Pfeifer Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 Nat. Genet. 25 2000 315 319
25. C. De Smet, A. Loriot, and T. Boon Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells Mol. Cell. Biol. 24 2004 4781 4790
26. F.E. Domann, J.C. Rice, M.J. Hendrix, and B.W. Futscher Epigenetic silencing of maspin gene expression in human breast cancers Int. J. Cancer 85 2000 805 810
27. M. Donadelli, C. Costanzo, L. Faggioli, M.T. Scupoli, P.S. Moore, C. Bassi, A. Scarpa, and M. Palmieri Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells Mol. Carcinogen. 38 2003 59 69
28. D.R. Duckett, S.M. Bronstein, Y. Taya, and P. Modrich hMutSalpha and MutLalpha dependent phosphorylation of p53 in response to DNA methylator damage Proc. Natl. Acad. Sci. U.S.A. 96 1999 12384 12388
29. A. Eden, F. Gaudet, A. Waghmare, and R. Jaenisch Chromosomal instability and tumors promoted by DNA hypomethylation Science 300 2003 455
30. T. Efferth, B.W. Futscher, and R. Osieka 5-Azacytidine modulates the response of sensitive and multidrug-resistant K562 leukemic cells to cytostatic drugs Blood Cells Mol. Dis. 27 2001 637 648
31. J.A. Ellerhorst, P. Frost, J.L. Abbruzzese, R.A. Newman, and Y. Chernajovsky 2′-Deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation Br. J. Cancer 67 1993 209 215
32. M. Esteller, and J.G. Herman Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours J. Pathol. 196 2002 1 7
33. M. Esteller, S.R. Hamilton, P.C. Burger, S.B. Baylin, and J.G. Herman Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res. 59 1999 793 797
34. M. Esteller, M. Sanchez-Cespedes, R. Rosell, D. Sidransky, S.B. Baylin, and J.G. Herman Detection of aberrant promoter hypermethylation of tumour suppressor genes in serum DNA from non-small cell lung cancer patients Cancer Res. 59 1999 67 70
35. M. Esteller, G. Gaidano, S.N. Goodman, V. Zagonel, D. Capello, B. Botto, D. Rossi, A. Gloghini, U. Vitolo, and A. Carbone Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma J. Natl. Cancer Inst. 94 2002 26 32
36. E. Evron, C.B. Umbricht, D. Korz, V. Raman, D.M. Loeb, B. Niranjan, L. Buluwela, S.A. Weitzman, J. Marks, and S. Sukumar Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation Cancer Res. 61 2001 2782 2787
37. W. Fischle, Y. Wang, and C.D. Allis Histone and chromatin cross-talk Curr. Opin. Cell Biol. 15 2003 172 183
38. M. Fournel, M.C. Trachy-Bourget, P.T. Yan, A. Kalita, C. Bonfils, C. Beaulieu, S. Frechette, S. Leit, E. Abou-Khalil, and S.H. Woo Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors Cancer Res. 62 2002 4325 4330
39. P. Frost, J.L. Abbruzzese, B. Hunt, D. Lee, and M. Ellis Synergistic cytotoxicity using 2′-deoxy-5-azacytidineand cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells Cancer Res. 50 1990 4572 4577
40. W.N. Fu, F. Bertoni, S.M. Kelsey, S.M. McElwaine, F.E. Cotter, A.C. Newland, and L. Jia Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia Oncogene 22 2003 451 455
41. S. Fulda, M.U. Kufer, E. Meyer, F. van Valen, B. Dockhorn-Dworniczak, and K.M. Debatin Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer Oncogene 20 2001 5865 5877
42. S. Fulda, and K.-M. Debatin Apoptosis pathways: turned on their heads? Drug Resist. Update 6 2003 1 3
43. B.W. Futscher, M.M. Oshiro, R.J. Wozniak, N. Holtan, C.L. Hanigan, H. Duan, and F.E. Domann Role for DNA methylation in the control of cell type specific maspin expression Nat. Genet. 31 2002 175 179
44. F. Gaudet, J.G. Hodgson, A. Eden, L. Jackson-Grusby, J. Dausman, J.W. Gray, H. Leonhardt, and R. Jaenisch Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
45. S.L. Gerson MGMT: its role in cancer aetiology and cancer therapeutics Nat. Rev. Cancer 4 2004 296 307
46. G. Gifford, J. Paul, P.A. Vasey, S.B. Kaye, and R. Brown The acquisition of hMLH1 methylation in plasma DNA following chemotherapy predicts poor survival for ovarian cancer patients Clin. Cancer Res. 10 3 2004 4420 4426
47. J. Goffin, and E. Eisenhauer DNA methyltransferase inhibitors-state of the art Ann. Oncol. 13 2002 1699 1716
48. J.R. Graff, J.G. Herman, R.G. Lapidus, H. Chopra, R. Xu, D.F. Jarrard, W.B. Isaacs, P.M. Pitha, N.E. Davidson, and S.B. Baylin E-Cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas Cancer Res. 55 1995 5195 5199
49. G.G. Gray, and T.J. Ekstrom The human histone deacetylase family Exp. Cell Res. 262 2001 75 83
50. C.Y. Gui, L. Ngo, W.S. Xu, V.M. Richon, and P.A. Marks Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 Proc. Natl. Acad. Sci. U.S.A. 101 2004 1241 1246
51. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
52. B. He, L. You, K. Uematsu, K. Zang, Z. Xu, A.Y. Lee, J.F. Costello, F. McCormick, and D.M. Jablons SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer Proc. Natl. Acad. Sci. U.S.A. 100 2003 14133 14138
53. E. Heard, P. Clerc, and P. Avner X-chromosome inactivation in mammals Ann. Rev. Genet. 31 1997 571 610
54. M.E. Hegi, A.C. Diserens, S. Godard, P.Y. Dietrich, L. Regli, S. Ostermann, P. Otten, G. Van Melle, N. de Tribolet, and R. Stupp Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin. Cancer Res. 10 2004 1871 1874
55. C. Henderson, and C. Brancolini Apoptotic pathways activated by histone deacetylase inhibitors: implications for the drug-resistant phenotype Drug Resist. Update 6 2003 231 296
56. J.G. Herman, F. Latif, Y. Weng, M.I. Lerman, B. Zbar, S. Liu, D. Samid, D.S. Duan, J.R. Gnarra, and W.M. Linehan Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma Proc. Natl. Acad. Sci. U.S.A. 91 1994 9700 9704
57. J.G. Herman, A. Merlo, L. Mao, R.G. Lapidus, J.P. Issa, N.E. Davidson, D. Sidransky, and S.B. Baylin Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers Cancer Res. 55 1995 4525 4530
58. J.G. Herman, J. Jen, A. Merlo, and S.B. Baylin Hypermethylation- associated inactivation indicates a tumor suppressor role for p15INK4B Cancer Res. 56 1996 722 727
59. S. Hopkins-Donaldson, A. Ziegler, S. Kurtz, C. Bigosch, D. Kandioler, C. Ludwig, U. Zangemeister-Wittke, and R. Stahel Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation Cell Death Differ. 10 2003 356 364
60. B.J. Iacopetta, D. Harmon, D.V. Spagnolo, A.K. House, and P.H. Kay Hypermethylation of the Myf-3 gene in human colorectal cancer Anticancer Res. 17 1997 429 432
61. R. Imanishi, A. Ohtsuru, M. Iwamatsu, T. Iioka, H. Namba, S. Seto, K. Yano, and S. Yamashita A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy J. Clin. Endocrinol. Metab. 87 2002 4821 4824
62. J.P. Issa Decitabine Curr. Opin. Oncol. 15 2003 446 451
63. J.P. Issa, G. Garcia-Manero, F.J. Giles, R. Mannari, D. Thomas, S. Faderl, E. Bayar, J. Lyons, C.S. Rosenfeld, J. Cortes, and H.M. Kantarjian Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies Blood 103 2004 1635 1640
64. H. Iwase, Y. Omoto, H. Iwata, T. Toyama, Y. Hara, Y. Ando, Y. Ito, Y. Fujii, and S. Kobayashi DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers Br. J. Cancer 80 1999 1982 1986
65. E.R. Jang, S.J. Lim, E.S. Lee, G. Jeong, T.Y. Kim, Y.J. Bang, and J.S. Lee The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen Oncogene 23 2004 1724 1736
66. P.J. Johnson, and Y.M.D. Lo Plasma nucleic acids in the diagnosis and management of malignant disease Clin. Chem. 48 2002 1186 1193
67. M.F. Kane, M. Loda, G.M. Gaida, J. Lipman, R. Mishra, H. Goldman, J.M. Jessup, and R. Kolodner Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines Cancer Res. 57 1997 808 811
68. J.H. Kang, S.J. Kim, D.Y. Noh, I.A. Park, K.J. Choe, O.J. Yoo, and H.S. Kang Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma Lab. Invest. 81 2001 573 579
69. P. Kantharidis, A. El-Osta, M. deSilva, D.M. Wall, X.F. Hu, A. Slater, G. Nadalin, J.D. Parkin, and J.R. Zalcberg Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance Clin. Cancer Res. 3 1997 2025 2032
70. P. Karran, and R. Hampson Genomic instability and tolerance to alkylating agents Cancer Surv. 28 1996 69 85
71. J.C. Keen, L. Yan, K.M. Mack, C. Pettit, D. Smith, D. Sharma, and N.E. Davidson A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine Breast Cancer Res. Treat. 81 2003 177 186
72. J.S. Kim, H.K. Jeung, J.W. Cheong, H. Maeng, S.T. Lee, J.S. Hahn, Y.W. Ko, and Y.H. Min Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades Br. J. Haematol. 124 2004 166 178
73. S.H. Kim, S. Ahn, J.W. Han, H.W. Lee, H.Y. Lee, Y.W. Lee, M.R. Kim, K.W. Kim, W.B. Kim, and S. Hong Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials Biochem. Biophys. Res. Commun. 315 2004 964 970
74. J.L. Kissil, E. Feinstein, O. Cohen, P.A. Jones, Y.C. Tsai, M.A. Knowles, M.E. Eydmann, and A. Kimchi DAP-kinase loss of expression in various carcinoma and B-cell lymphoma cell lines: possible implications for role as tumor suppressor gene Oncogene 15 1997 403 407
75. H. Kobayashi, E.M. Tan, and S.E. Fleming Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells Int. J. Cancer 109 2004 207 213
76. S.L. Kominsky, P. Argani, D. Korz, E. Evron, V. Raman, E. Garrett, A. Rein, G. Sauter, O.P. Kallioniemi, and S. Sukumar Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast Oncogene 22 2003 2021 2033
77. M. Lachner, D. O'Carroll, S. Rea, K. Mechtler, and T. Jenuwein Methylation of histone H3 lysine 9 creates a binding site for HP1 protein Nature 410 2001 116 120
78. M. Lachner, R.J. O'Sullivan, and T. Jenuwein An epigenetic road map for histone lysine methylation J. Cell Sci. 116 2003 2117 2124
79. P.W. Laird, L. Jackson-Grusby, A. Fazeli, S.L. Dickinson, W.E. Jung, E. Li, R.A. Weinberg, and R. Jaenisch Suppression of intestinal neoplasia by DNA hypomethylation Cell 81 1995 197 205
80. W.H. Lee, R.A. Morton, J.I. Epstein, J.D. Brooks, P.A. Campbell, G.S. Bova, W.S. Hsieh, W.B. Isaacs, and W.G. Nelson Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis Proc. Natl. Acad. Sci. U.S.A. 91 1994 11733 11737
81. E. Li, C. Beard, and R. Jaenisch Role for DNA methylation in genomic imprinting Nature 366 1993 362 365
82. Q. Li, N. Ahuja, P.C. Burger, and J.P. Issa Methylation and silencing of the Thrombospondin-1 promoter in human cancer Oncogene 18 1999 3284 3289
83. Y. Li, H. Nagai, T. Ohno, M. Yuge, S. Hatano, E. Ito, N. Mori, H. Saito, and T. Kinoshita Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype Blood 100 2002 2572 2577
84. X. Li, J.K. Cowell, and K. Sossey-Alaoui CLCA2 tumour suppressor gene in 1p31 is epigenetically regulated in breast cancer Oncogene 23 2004 1474 1480
85. K. Liu, Y.F. Wang, C. Cantemir, and M.T. Muller Endogenous assays of DNA methyltransferases: Evidence for differential activities of DNMT1, DNMT2, and DNMT3 in mammalian cells in vivo Mol. Cell. Biol. 23 2003 2709 2719
86. L.T. Liu, H.C. Chang, L.C. Chiang, and W.C. Hung Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion Cancer Res. 63 2003 3069 3072
87. J. Lyons, E. Bayar, G. Fine, M. McCullar, R. Rolens, J. Rubinfeld, and C. Rosenfeld Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies Curr. Opin. Invest. Drugs 4 2003 1442 1450
88. P.A. Marks, V.M. Richon, and R.A. Rifkind Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 13 2000 477 483
89. P.A. Marks, V.M. Richon, R. Breslow, and R.A. Rifkind Histone deacetylase inhibitors as new cancer drugs Curr. Opin. Oncol. 13 2002 477 483
90. C.J. Marsit, M. Liu, H.H. Nelson, M. Posner, M. Suzuki, and K.T. Kelsey Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival Oncogene 23 2004 1000 1004
91. J. Mattern, U. Eichhorn, B. Kaina, and M. Volm O6-Methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts Int. J. Cancer 77 1998 919 922
92. L.M. Mielnicki, A.M. Ying, K.L. Head, H.L. Asch, and B.B. Asch Epigenetic regulation of gelsolin expression in human breast cancer cells Exp. Cell Res. 249 1999 161 176
93. R.L. Momparler, B.T. Dore, and L.F. Momparler Effect of 5-aza-2′-deoxycytidine and retinoic acid on differentiation and c-myc expression in HL-60 myeloid leukemic cells Cancer Lett. 54 1990 21 28
94. N.J. Moreland, M. Illand, Y.T. Kim, J. Paul, and R. Brown Modulation of drug resistance mediated by loss of mismatch repair by the DNA polymerase inhibitor aphidicolin Cancer Res. 59 1999 2102 2106
95. S. Nakatsuka, A. Liu, M. Yao, T. Takakuwa, Y. Tomita, Y. Hoshida, M. Nishiu, and K. Aozasa Methylation of promoter region in p27 gene plays a role in the development of lymphoid malignancies Int. J. Oncol. 22 2003 561 568
96. J. Neuzil, E. Swettenham, and N. Gellert Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation Biochem. Biophys. Res. Commun. 314 2004 186 191
97. N. Ohtani-Fujita, T. Fujita, A. Aoike, N.E. Osifchin, P.D. Robbins, and T. Sakai CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene Oncogene 8 1993 1063 1067
98. T. Oka, M. Ouchida, M. Koyama, Y. Ogama, S. Takada, Y. Nakatani, T. Tanaka, T. Yoshino, K. Hayashi, and N. Ohara Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas Cancer Res. 62 2002 6390 6394
99. O.I. Olopade, and M. Wei FANCF methylation contributes to chemoselectivity in ovarian cancer Cancer Cell 3 2003 417 420
100. W.A. Palmisano, K.P. Crume, M.J. Grimes, S.A. Winters, M. Toyota, M. Esteller, N. Joste, S.B. Baylin, and S.A. Belinsky Aberrant promoter methylation of the transcription factor genes PAX5 alpha and beta in human cancers Cancer Res. 63 2003 4620 4625
101. E. Papouli, P. Cejka, and J. Jiricny Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells Cancer Res. 64 2004 3391 3394
102. M. Pinto, C. Oliveira, L. Cirnes, J. Carlos Machado, M. Ramires, A. Nogueira, F. Carneiro, and R. Seruca Promoter methylation of TGFbeta receptor I and mutation of TGFbeta receptor II are frequent events in MSI sporadic gastric carcinomas J. Pathol. 200 2003 32 38
103. J.A. Plumb, G. Strathdee, J. Sludden, S.B. Kaye, and R. Brown Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine- induced demethylation of the hMLH1 gene promoter Cancer Res. 60 2000 6039 6044
104. Y. Pommier, O. Sordet, S. Antony, R.L. Hayward, and K.W. Kohn Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks Oncogene 23 2004 2934 2949
105. M. Primeau, J. Gagnon, and R.L. Momparler Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells Int. J. Cancer 103 2003 177 184
106. X.C. Qian, and T.P. Brent Methylation hot spots in the 5′ flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene Cancer Res. 57 1997 3672 3677
107. I. Rhee, K.E. Bachman, B.H. Park, K.W. Jair, R.W. Yen, K.E. Schuebel, H. Cui, A.P. Feinberg, C. Lengauer, and K.W. Kinzler DNMT1 and DNMT3b cooperate to silence genes in human cancer cells Nature 416 2002 552 556
108. V.M. Richon, T.W. Sandhoff, R.A. Rifkind, and P.A. Marks Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc. Natl. Acad. Sci. U.S.A. 97 2000 10014 10019
109. K.D. Robertson, and P.A. Jones The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53 Mol. Cell. Biol. 18 1998 6457 6473
110. J. Roman-Gomez, J.A. Castillejo, A. Jimenez, M.G. Gonzalez, F. Moreno, M.C. Rodriguez, M. Barrios, J. Maldonado, and A. Torres 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia Blood 99 2002 2291 2296
111. A. Saleh, S.M. Srinivasula, S. Acharya, R. Fishel, and E.S. Alnemri Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation J. Biol. Chem. 274 1999 17941 17945
112. H.B. Salvesen, N. MacDonald, A. Ryan, I.J. Jacobs, E.D. Lynch, L.A. Akslen, and S. Das PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma Int. J. Cancer 91 2001 22 26
113. H. Santos-Rosa, R. Schneider, A.J. Bannister, J. Sherriff, B.E. Bernstein, N.C. Emre, S.L. Schreiber, J. Mellor, and T. Kouzarides Active genes are tri-methylated at K4 of histone H3 Nature 419 2002 407 411
114. S. Santourlidis, U. Warskulat, A.R. Florl, S. Maas, T. Pulte, J. Fischer, W. Muller, and W.A. Schulz Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kappaB sites in prostatic carcinoma Mol. Carcinogen. 32 2001 36 43
115. U.G. Sathyanarayana, S. Toyooka, A. Padar, T. Takahashi, E. Brambilla, J.D. Minna, and A.F. Gazdar Epigenetic inactivation of laminin-5-encoding genes in lung cancers Clin. Cancer Res. 9 2003 2665 2672
116. N. Sato, T. Ohta, H. Kitagawa, M. Kayahara, I. Ninomiya, S. Fushida, T. Fujimura, G. Nishimura, K. Shimizu, and K. Miwa FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells Int. J. Oncol. 24 2004 679 685
117. G.C. Sellar, K.P. Watt, G.J. Rabiasz, E.A. Stronach, L. Li, E.P. Miller, C.E. Massie, J. Miller, B. Contreras-Moreira, and D. Scott OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer Nat. Genet. 34 2003 337 343
118. H. Shimodaira, A. Yoshioka-Yamashita, R.D. Kolodner, and J.Y. Wang Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin Proc. Natl. Acad. Sci. U.S.A. 100 2003 2420 2425
119. J.R. Silber, M.S. Bobola, S. Ghatan, A. Blank, D.D. Kolstoe, and M.S. Berger O6-Methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics Cancer Res. 58 1998 1068 1073
120. J.R. Silber, A. Blank, M.S. Bobola, S. Ghatan, D.D. Kolstoe, and M.S. Berger O6-Methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy Clin. Cancer Res. 5 1999 807 814
121. E.A. Slee, C. Adrain, and S.J. Martin Serial killers: ordering caspase activation events in apoptosis Cell Death Differ. 6 1999 1067 1074
122. M.S. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller, X. Opitz-Araya, R. McCombie, J.G. Herman, W.L. Gerald, and Y.A. Lazebnik Inactivation of the apoptosis effector Apaf-1 in malignant melanoma Nature 409 2001 207 211
123. K.M. Stimson, and P.M. Vertino Methylation-mediated silencing of TMS1/ASC is accompanied by histone hypoacetylation and CpG island-localized changes in chromatin architecture J. Biol. Chem. 277 2002 4951 4958
124. L. Stojic, N. Mojas, P. Cejka, M. Di Pietro, S. Ferrari, G. Marra, and J. Jiricny Mismatch repair-dependent G2 checkpoint induced by low doses of SN1 type methylating agents requires the ATR kinase Genes Dev. 18 2004 1331 1344
125. B.D. Strahl, and C.D. Allis The language of covalent histone modifications Nature 403 2000 41 45
126. G. Strathdee, M. MacKean, M. Illand, and R. Brown A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer Oncogene 18 1999 2335 2341
127. G. Strathdee, B.R. Davies, J.K. Vass, N. Siddiqui, and R. Brown Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene Carcinogenesis 25 2004 693 701
128. K. Struhl Histone acetylation and transcriptional regulatory mechanisms Genes Dev. 12 1998 599 606
129. E.R. Suh, C.S. Ha, E.B. Rankin, M. Toyota, and P.G. Traber DNA methylation down-regulates CDX1 gene expression in colorectal cancer cell lines J. Biol. Chem. 277 2002 35795 35800
130. M. Szyf DNA methylation and cancer therapy Drug Resist. Update. 6 2003 341 353
131. T. Taniguchi, M. Tischkowitz, N. Ameziane, S.V. Hodgson, C.G. Mathew, H. Joenje, S.C. Mok, and A.D. D'Andrea Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat. Med. 9 2003 568 574
132. P.H. Tate, and A. Bird Effects of DNA methylation on DNA binding proteins and gene expression Curr. Opin. Genet. Dev. 3 1993 226 231
133. S.M. Taylor, and P.A. Jones Multiple new phenotypes induced in 10T2 and 3T3 cells treatefd with 5-azacytidine Cell 17 1979 771 779
134. T. Teitz, T. Wei, M.B. Valentine, E.F. Vanin, J. Grenet, V.A. Valentine, F.G. Behm, A.T. Look, J.M. Lahti, and V.J. Kidd Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN Nat. Med. 6 2000 529 535
135. M. Tischkowitz, N. Ameziane, Q. Waisfisz, J.P. De Winter, R. Harris, T. Taniguchi, A. D'Andrea, S.V. Hodgson, C.G. Mathew, and H. Joenje Bi-allelic silencing of the Fanconi anaemia gene FANCF in acute myeloid leukaemia Br. J. Haematol. 123 2003 469 471
136. K.O. Toyooka, S. Toyooka, A.K. Virmani, U.G. Sathyanarayana, D.M. Euhus, M. Gilcrease, J.D. Minna, and A.F. Gazdar Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas Cancer Res. 61 2001 4556 4560
137. M. Toyota, N. Ahuja, M. Ohe-Toyota, J.G. Herman, S.B. Baylin, and J.P. Issa CpG island methylator phenotype in colorectal cancer Proc. Natl. Acad. Sci. U.S.A. 96 1999 8681 8686
138. M. Toyota, K.J. Kopecky, M.O. Toyota, K.W. Jair, C.L. Willman, and J.P. Issa Methylation profiling in acute myeloid leukemia Blood 97 2001 2823 2829
139. J.K. Tyler, and J.T. Kadonaga The "dark side" of chromatin remodelling: repressive effects on transcription Cell 99 1999 443 446
140. C.B. Umbricht, E. Evron, E. Gabrielson, A. Ferguson, J. Marks, and S. Sukumar Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer Oncogene 20 2001 3348 3353
141. C. Van Lint, S. Emiliani, and E. Verdin The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation Gene Expr. 5 1996 245 253
142. N.S. Verkaik, J. Trapman, J.C. Romijn, T.H. Van der Kwast, and G.J. Van Steenbrugge Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation Int. J. Cancer 80 1999 439 443
143. P.M. Vertino, J.A. Sekowski, J.M. Coll, N. Applegren, S. Han, R.J. Hickey, and L.H. Malkas DNMT1 is a component of a multiprotein DNA replication complex Cell Cycle 1 2002 416 423
144. C.P. Walsh, J.R. Chaillet, and T.H. Bestor Transcription of IAP endogenous retroviruses is constrained by cytosine methylation Nat. Genet. 20 1998 116 117
145. R.P. Warrell Jr., L.Z. He, V. Richon, E. Calleja, and P.P. Pandolfi Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase J. Natl. Cancer Inst. 90 1998 1621 1625
146. S.H. Wei, C.M. Chen, G. Strathdee, J. Harnsomburana, C.R. Shyu, F. Rahmatpanah, H. Shi, S.W. Ng, P.S. Yan, and K.P. Nephew Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers Clin. Cancer Res. 8 2002 2246 2252
147. S.H. Wei, R. Brown, and T.H. Huang Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann. N.Y. Acad. Sci. 983 2003 243 250
148. B.P. Whitcomb, D.G. Mutch, T.J. Herzog, J.S. Rader, R.K. Gibb, and P.J. Goodfellow Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma Clin. Cancer Res. 9 2003 2277 2287
149. J. Worm, A.F. Kirkin, K.N. Dzhandzhugazyan, and P. Guldberg Methylation-dependent silencing of the reduced folate carrier gene in inherently methotrexate-resistant human breast cancer cells J. Biol. Chem. 276 2001 39990 40000
150. Y. Yamada, H. Watanabe, F. Miura, H. Soejima, M. Uchiyama, T. Iwasaka, T. Mukai, Y. Sakaki, and T. Ito A comprehensive analysis of allelic methylation status of CpG islands on human chromosome 21q Genome Res. 14 2004 247 266
151. Y. Yamashita, M. Shimada, N. Harimoto, T. Rikimaru, K. Shirabe, S. Tanaka, and K. Sugimachi Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells Int. J. Cancer 103 2003 572 576
152. B.Z. Yuan, M.E. Durkin, and N.C. Popescu Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers Cancer Genet. Cytogenet. 140 2003 113 117